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Abstract
Background: In a genome-wide association scan, the single-nucleotide polymorphism (SNP) rs738409 in the
patatin-like phospholipase 3 gene (PNPLA3) was strongly associated with increased liver fat content. We
investigated whether this SNP is associated with the occurrence and progression of nonalcoholic fatty liver disease
(NAFLD) in the Japanese population.
Methods: SNP rs738409 was genotyped by the Taqman assay in 253 patients with NAFLD (189 with nonalcoholic
steatohepatitis [NASH] and 64 with simple steatosis) and 578 control subjects. All patients with NAFLD underwent
liver biopsy. Control subjects had no metabolic disorders. For a case-control study, the c
2-test (additive model) was
performed. Odds ratios (ORs) were adjusted for age, gender, and body mass index (BMI) by using multiple logistic
regression analysis with genotypes (additive model), age, gender, and BMI as the independent variables. Multiple
linear regression analysis was performed to test the independent effect of risk allele on clinical parameters while
considering the effects of other variables (age, gender, and BMI), which were assumed to be independent of the
effect of the SNP.
Results: The risk allele (G-allele) frequency of rs738409 was 0.44 in the control subjects and 0.60 in patients with
NAFLD; this shows a strong association with NAFLD (additive model, P = 9.4 × 10
-10). The OR (95% confidence
interval) adjusted for age, gender, and BMI was 1.73 (1.25-2.38). Multiple linear regression analysis indicated that the
G-allele of rs738409 was significantly associated with increases in aspartate transaminase (AST) (P = 0.00013),
alanine transaminase (ALT) (P = 9.1 × 10
-6), and ferritin levels (P = 0.014), and the fibrosis stage (P = 0.011) in the
patients with NAFLD, even after adjustment for age, gender, and BMI. The steatosis grade was not associated with
rs738409.
Conclusions: We found that in the Japanese population, individuals harboring the G-allele of rs738409 were
susceptible to NAFLD, and that rs738409 was associated with plasma levels of ALT, AST, and ferritin, and the
histological fibrosis stage. Our study suggests that PNPLA3 may be involved in the progression of fibrosis in NAFLD.
Background
Nonalcoholic fatty liver disease (NAFLD) is now recog-
nized as an important health concern [1,2]. NAFLD has a
broad spectrum of manifestations, ranging from simple
steatosis, its inflammatory counterpart nonalcoholic stea-
tohepatitis (NASH), fibrosis/cirrhosis, to hepatocellular
carcinoma. Excess fat accumulation in the liver is
observed in 20-30% of the population of American and
European countries where NASH is associated with
approximately 1-3% of the population [3], and NAFLD is
now considered to be a part of the metabolic syndrome
[4]. According to recent data, fatty liver may not only be
a manifestation of, but also induce insulin resistance by
producing specific proteins such as, fetuin-A [5-7].
Genetic as well as environmental factors are important in
the development of NAFLD [8-11]. Single-nucleotide
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genetic factors and have been intensively investigated in
various common diseases. Variations in peroxisome pro-
liferator-activated receptor g coactivator 1a
(PPARGC1A), angiotensin II type 1 receptor (ATGR1),
and nitric oxide synthase 2 (inducible) (NOS2) genes
were found to be associated with NAFLD in Japanese
individuals [12-14]. Variations in the adiponectin recep-
tor 1 (ADIPOR1) and diacylglycerol O-acyltransferase 2
(DGAT2) genes have been reported to be associated with
fatty liver and insulin resistance in the Caucasian popula-
tion [15,16].
Recent genome-wide association studies revealed that
the genetic variation rs738409 (I148M) in PNPLA3
influences NAFLD and plasma levels of liver enzymes
[17-19]; replication studies suggesting the same have
also been reported [20-26]. However, the association of
rs738409 with the development and severity of NAFLD
in the Asian population has not yet been reported. In
the present study, we investigated the association
between rs738409 in PNPLA3 and NAFLD in the Japa-
nese population and found significant associations
between rs738409 and NAFLD, plasma levels of liver
enzymes, and liver fibrosis.
Methods
Subjects
In the present study, the subjects were 253 Japanese
patients with NAFLD (189 with NASH and 64 with sim-
ple steatosis), and 578 healthy Japanese individuals (con-
trols). All of the 253 patients with NAFLD underwent
liver biopsy. Liver biopsy tissues were stained with
hematoxylin and -eosin, Masson’s trichrome, and reticu-
lin silver stain. The histological criterion for the diagno-
sis of NAFLD is macrovesicular fatty change in
hepatocytes with displacement of the nucleus toward
the edge of the cell [27]. When more than 5% of the
hepatocytes are affected by macrovesicular steatosis,
patients are diagnosed as having either steatosis or stea-
tohepatitis. In addition to steatosis, the criteria for the
diagnosis of steatohepatitis are lobular inflammation and
the presence of either ballooning cells or hepatic fibrosis
containing perisinusoidal/pericellular fibrosis [28,29].
The degree of steatosis was graded as follows on the
basis of the percentage of hepatocytes containing macro-
vesicular fat droplets: grade 0, no steatosis; grade 1,
<33% hepatocytes containing macrovesicular fat dro-
plets; grade 2, 33-66% of hepatocytes containing macro-
vesicular fat droplets; grade 3, >66% of hepatocytes
containing macrovesicular fat droplets. The severity of
the fibrosis was scored according to the method of
Brunt [30]. The severity of the fibrosis was expressed
on a 4-point scale, as follows: 0, none; 1, perivenular
and/or perisinusoidal fibrosis in zone 3; 2, combined
pericellular portal fibrosis; 3, septal/bridging fibrosis; 4,
cirrhosis. Patients with the following diseases were
excluded from this study: infectious hepatitis (hepatitis
B and C, Epstein-Barr virus infection), autoimmune
hepatitis, primary biliary cirrhosis, sclerosing cholangitis,
hemochromatosis, a1-antitrypsin deficiency, Wilson’s
disease, drug-induced hepatitis, alcoholic hepatitis, and
excessive alcohol consumption (present or past daily
consumption of more than 20 g alcohol per day). No
patient had any clinical evidence of hepatic decompen-
sation, such as hepatic encephalopathy, ascites, variceal
bleeding, or a serum bilirubin level greater than 2-fold
the upper limit of normal. Among 253 NAFLD patients,
53 subjects had type 2 diabetes and 45 patients were
under treatment: 13 patients being treated with pioglita-
zone, 6 with insulin, and the others with oral hypoglyce-
mic agents other than pioglitazone. Two hundred nine
patients had dyslipidemia and 81 were undergoing pre-
scribed treatment: statines (67 patients), fibrates
(10 patients), or other drugs (4 patients). One hundred
fifty-three patients had hypertension and 54 patients
were being treated with antihypertensive drugs: 36
patients were being treated with angiotensin receptor
blockers (ARBs) and the others were being treated with
other drugs such as calcium channel blockers.
All control subjects were confirmed to have normal
liver function. Control subjects had no risk of fatty
liver, which was determined from the following para-
meters: body mass index (BMI), <25 kg/m
2;f a s t i n g
plasma glucose, <110 mg/dL; serum triglycerides,
<150 mg/dL, serum high-density lipoprotein (HDL)
cholesterol, >40 mg/dL; systolic blood pressure,
<130 mm Hg; and diastolic blood pressure, <85 mm Hg.
The clinical features of the subjects are summarized in
Tables 1 and 2.
All the investigations performed in this study were
conducted in accordance with the guidelines of the 1975
Declaration of Helsinki. Written informed consent was
obtained from each subject, and the protocol was
approved by the ethics committee of the Kyoto Univer-
s i t y ,Y o k o h a m aC i t yU n i v e r s i t y ,H i r o s h i m aU n i v e r s i t y ,
and Kurume University.
Clinical and laboratory evaluation
The weight and height of the patients were measured
with a calibrated scale after removing shoes and heavy
clothing, if any. Venous blood samples were obtained
from the subjects after an overnight fast (12 h) for the
measurement of plasma glucose, serum aspartate transa-
minase (AST), alanine transaminase (ALT), hemoglobin
A1c (HbA1c), total cholesterol, HDL cholesterol, trigly-
cerides, iron, ferritin, hyaluronic acid, and type IV col-
lagen 7S. All laboratory biochemical parameters were
measured in a conventional automated analyzer.
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Genomic DNA was extracted using Genomix (Talent
Srl, Trieste, Italy) from blood samples collected from
each subject. A predesigned TaqMan probe (Applied
Biosystems, Foster City, CA) was purchased for genotyp-
ing of rs738409 (C_7241_10) and genotyping was carried
out according to the manufacturer’sp r o t o c o l .T h es u c -
cess rates of these assays were >99.0%.
Statistical analysis
For each case-control study, the c
2-test (additive model)
was performed according to Sladek et al.[ 3 1 ] .W e
coded genotypes as 0, 1, and 2, depending on the num-
ber of copies of the risk allele. Odds ratios (ORs)
adjusted for age, gender, and BMI were calculated using
multiple logistic regression analysis with genotypes, age,
gender, and BMI as the independent variables. The
Hardy-Weinberg equilibrium was assessed using the
c
2-test [32]. Simple comparison of the clinical data
between case and control groups was carried out using
the Mann-Whitney U test. Simple comparison of the
clinical data in the different genotypes was carried out
using the Kruskal-Wallis test. Multiple linear regression
analysis was performed to test the independent effect of
risk allele on clinical parameters considering the effects
of other variables (age, gender, and BMI), which were
assumed to be independent of the effect of the SNP.
The significance of the association between an indepen-
dent and dependent variables was tested using the t test.
The values of triglycerides, ferritin, and hyaluronic acid
were logarithmically transformed before performing the
multiple linear regression analysis. Statistical analysis
was performed using the software R http://www.r-
project.org/.
Results
Case-control association study
The clinical data of patients in the NAFLD and control
groups are presented in Table 1. The clinical and bio-
chemical characteristics of the patients with NASH and
of those with simple steatosis are shown in Table 2. The
risk allele (G-allele) frequency of rs738409 in the control
subjects was 0.44, which was almost the same as that
reported in the HapMap database but higher than that
in other populations (such as European and African
American). The risk allele frequency in the NAFLD
patients was 0.60, and rs738409 showed a strong asso-
ciation with NAFLD (P =9 . 4×1 0
-10; Table 3). The OR
for the heterozygotes was 1.46 and that for the homozy-
gotes was 3.63, indicating an allele-dependent dose
effect. The number of women, and the age and BMI of
patients in the NAFLD group were higher than those of
individuals in the control group. Even after the para-
meters of gender and age were adjusted for, rs738409
Table 1 Clinical characteristics of the patients with NAFLD and control subjects
NAFLD (n = 253) Control (n = 578) P value
Men/women 122/131 182/396 <0.0001*
Age (year) 51.7 ± 15.0
(38.0; 52.5; 64.0)
47.2 ± 14.8
(34.0; 49.0; 57.0)
<0.0001
BMI (kg/m
2) 27.7 ± 5.3
(24.4; 27.3; 29.8)
21.3 ± 2.2
(19.8; 21.4; 23.1)
<0.0001
FBS (mg/dL) 117.1 ± 34.6
(99.0; 108.0; 124.0)
90.9 ± 7.7
(85.0; 90.5; 96.0)
<0.0001
HbA1c (%) 5.9 ± 1.2
(5.1; 5.5; 6.3)
5.0 ± 0.4
(4.8; 5.0; 5.3)
<0.0001
Total cholesterol (mg/dL) 212.3 ± 37.9
(183.0; 212.0; 237.0)
202.3 ± 34.4
(177.0; 202.0; 223.0)
0.0014
Triglycerides (mg/dL) 169.9 ± 97.7
(112.0; 148.0; 205.0)
75.7 ± 28.6
(53.0; 70.0; 95.0)
<0.0001
HDL cholesterol (mg/dL) 52.5 ± 17.4
(42.0; 49.0; 58.0)
67.4 ± 14.0
(57.0; 66.0; 75.8)
<0.0001
Systolic blood pressure (mm Hg) 126.7 ± 15.5
(114.0; 125.0; 138.0)
111.1 ± 10.2
(104.0; 112.0; 120.0)
<0.0001
Diastolic blood pressure (mm Hg) 77.5 ± 11.4
(70.0; 78.0; 86.0)
69.4 ± 7.5
(64.0; 70.0; 75.8)
<0.0001
AST (IU/L) 48.6 ± 29.7
(27.0; 37.0; 64.0)
19.9 ± 6.4
(15.0; 18.0; 23.0)
<0.0001
ALT (IU/L) 76.2 ± 50.7
(37.8; 61.0; 93.3)
15.6 ± 6.4
(11.0; 14.0; 19.0)
<0.0001
Data are represented as the mean ± SD (25
th,5 0
th, and 75
th percentile). P values were obtained by comparing the quantitative phenotype between 2 groups
(Mann-Whitney U test). *Men/women ratio was analyzed by Fisher’s exact test. AST, aspartate transaminase; ALT, alanine transaminase; BMI, body mass index;
FBS, fasting blood sugar; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; NAFLD, nonalcoholic fatty liver disease.
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-8).
When the case-control association study was performed
separately in men and women, significant associations
were observed (P = 0.00017 in men and 1.6 × 10
-6 in
women; Additional file 1 Table S1). When the para-
meters of gender, age, and BMI were adjusted for, this
association was significant (P = 0.00087). The OR (95%
confidence interval [CI]) adjusted for age, gender, and
BMI was 1.73 (1.25-2.38). We divided the NAFLD
group into the NASH and simple steatosis groups and
performed case-control association studies. The risk
allele frequency in the simple steatosis group was 0.50,
and that in the NASH group was 0.64, which was the
highest among the 3 groups. A significant association
was observed between NASH and control groups (P =
1.8 × 10
-11), and between NASH and simple steatosis
groups (P = 0.0083). Significant association with NASH
was observed even after adjusting for parameters of gen-
der and age (P =5 . 7×1 0
-10), and gender, age, and BMI
(P = 0.00082). No significant association between the
simple steatosis group and the control group was
observed. The genotype of rs738409 was in Hardy-
Weinberg equilibrium in the 3 groups (P > 0.05). Thus,
the rs738409 genotype may be associated with the pro-
gression of NAFLD.
Analysis of various quantitative phenotypes with the
rs738409 SNP
To investigate whether the genotypes of rs738409 were
associated with clinical parameters, we compared age,
BMI, fasting plasma glucose, HbA1c, total cholesterol,
triglycerides, HDL cholesterol, AST, ALT, iron, ferritin,
Table 2 Clinical characteristics of patients with NASH and simple steatosis
NASH
(n = 189)
Simple steatosis (n = 64) P value
Men/women 99/90 23/41 0.030*
Age (year) 51.8 ± 15.7
(37.0; 52.5; 65.0)
51.3 ± 13.1
(44.0; 52.5; 61.0)
0.93
BMI (kg/m
2) 28.5 ± 5.6
(25.3; 28.1; 30.4)
25.3 ± 3.5
(22.4; 24.7; 27.5)
<0.0001
FBS (mg/dL) 116.7 ± 31.5
(100.0; 108.0; 124.0)
118.0 ± 41.7
(95.8; 105.5; 122.0)
0.27
HbA1c (%) 5.9 ± 1.2
(5.1; 5.6; 6.3)
5.8 ± 1.3
(5.0; 5.3; 6.3)
0.22
Total cholesterol (mg/dL) 210.0 ± 37.3
(183.0; 210.0; 232.0)
218.0 ± 39.0
(189.5; 217.0; 249.0)
0.12
Triglycerides (mg/dL) 174.6 ± 103.9
(115.0; 149.0; 211.0)
158.2 ± 80.0
(104.0; 147.0; 195.5)
0.29
HDL cholesterol (mg/dL) 51.7 ± 18.1
(41.0; 48.0; 57.3)
54.6 ± 15.5
(44.0; 54.0; 60.5)
0.049
Systolic blood pressure (mm Hg) 127.8 ± 15.4
(118.0; 126.0; 140.0)
124.2 ± 15.7
(111.0; 124.0; 137.0)
0.13
Diastolic blood pressure (mm Hg) 77.8 ± 11.3
(70.0; 78.0; 85.0)
76.9 ± 11.9
(68.5; 76.0; 87.0)
0.58
AST (IU/L) 55.2 ± 31.3
(32.0; 45.0; 69.0)
32.5 ± 16.8
(21.0; 27.0; 36.3)
<0.0001
ALT (IU/L) 87.0 ± 53.2
(51.0; 76.0; 103.0)
49.7 ± 31.1
(30.8; 41.0; 47.3)
<0.0001
Iron (ng/mL) 111.7 ± 35.5
(91.0; 114.5; 134.0)
106.1 ± 26.1
(85.5; 100.0; 123.8)
0.087
Ferritin (ng/mL) 278.1 ± 246.5
(98.0; 204.4; 379.0)
181.2 ± 172.5
(84.0; 131.0; 175.2)
0.0036
Hyaluronic acid (ng/dL) 54.0 ± 68.5
(16.0; 32.0; 75.0)
26.7 ± 20.5
(9.0; 23.0; 36.5)
0.0048
Type IV collagen 7S (ng/dL) 4.9 ± 1.5
(3.9; 4.7; 5.5)
3.8 ± 0.7
(3.5; 3.7; 4.1)
<0.0001
Steatosis grade 1.7 ± 0.7
(1.0; 2.0; 2.0)
1.3 ± 0.5
(1.0; 1.0; 2.0)
<0.0001
Fibrosis stage 1.4 ± 0.8
(1.0; 1.0; 2.0)
0.1 ± 0.4
(0.0; 0.0; 0.0)
<0.0001
Data are represented as the mean ± SD (25
th,5 0
th, and 75
th percentile). P values were obtained by comparing the quantitative phenotype between 2 groups
(Mann-Whitney U test). *Men/women ratio was analyzed by Fisher’s exact test. AST, aspartate transaminase; ALT, alanine transaminase; BMI, body mass index;
FBS, fasting blood sugar; HbA1c, hemoglobin A1c; HDL; high-density lipoprotein; NASH, nonalcoholic steatohepatitis.
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Page 4 of 10Table 3 Genotype frequencies and association tests of rs738409 in PNPLA3 in patients with NAFLD and control
subjects
Genotype
CC/CG/GG
Risk allele
(G)
frequency
P value (additive model) OR (95% CI) HWE
Unadjusted Adjusted for
age and
gender
Adjusted for
age, gender and
BMI
Heterogyotes Homogyotes Additive
model *
P
value
NAFLD vs. control
NAFLD 45/111/97 0.60 9.4 × 10
-10 1.9 × 10
-8 0.00087 1.46 (0.98 - 2.16) 3.63 (2.36 - 5.57) 1.73 (1.25 - 2.38) 0.18
Control 175/296/
104
0.44 0.28
NASH vs. control
NASH 26/85/78 0.64 1.8 × 10
-11 5.7 × 10
-10 0.00082 1.93 (1.20 - 3.12) 5.05 (3.04 - 8.37) 2.00 (1.33 - 3.00) 0.71
Control 175/296/
104
0.44 0.28
NASH vs. simple steatosis
NASH 26/85/78 0.64 0.0083 0.010 0.021 2.39 (1.14 - 4.99) 3.00 (1.38 - 6.51) 1.65 (1.08 - 2.51) 0.71
Simple
steatosis
19/26/19 0.50 0.13
Simple steatosis vs. control
Simple
steatosis
19/26/19 0.50 0.18 0.24 0.16 0.81 (0.44 - 1.50) 1.68 (0.85 - 3.32) 1.37 (0.88 - 2.14) 0.13
Control 175/296/
104
0.44 0.28
CI, confidence interval; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; HWE, Hardy-Weinberg equilibrium; OR, odds ratio. * The OR
was adjusted simultaneously for age, gender, and BMI using the additive model.
Table 4 Comparison of various quantitative phenotypes among the different genotypes at rs738409 in PNPLA3 in
patients with NAFLD and control subjects
Quantitative phenotype NAFLD * Control *
CC (n = 45) CG (n = 111) GG (n = 97) P value
§ CC (n = 175) CG (n = 296) GG (n = 104) P value
§
Age (year) 53.4 ± 11.2 48.6 ± 15.0 54.5 ± 16.0 0.019 45.6 ± 14.9 47.6 ± 14.5 48.9 ± 15.7 0.17
BMI (kg/m
2) 26.8 ± 4.9 28.0 ± 4.4 27.8 ± 6.3 0.16 21.2 ± 2.2 21.4 ± 2.1 21.4 ± 2.0 0.75
FBS (mg/dL) 121.2 ± 28.7 117.5 ± 38.2 114.5 ± 33.1 0.014 90.0 ± 7.8 91.4 ± 7.6 90.7 ± 7.4 0.23
HbA1c (%) 6.0 ± 1.2 5.9 ± 1.3 5.8 ± 1.1 0.36 5.0 ± 0.3 5.0 ± 0.4 5.1 ± 0.3 0.78
Total cholesterol (mg/dL) 217.4 ± 32.8 209.7 ± 40.6 212.6 ± 37.2 0.38 198.6 ± 34.0 203.7 ± 33.7 203.6 ± 36.6 0.25
Triglycerides (mg/dL) 175.3 ± 81.4 188.0 ± 119.5 146.2 ± 69.0 0.0055 75.7 ± 29.1 76.5 ± 29.0 72.9 ± 27.0 0.56
HDL cholesterol (mg/dL) 54.6 ± 21.0 50.6 ± 17.6 53.7 ± 15.0 0.20 65.4 ± 13.3 68.0 ± 13.9 69.1 ± 14.9 0.073
SBP (mm Hg) 128.3 ± 14.8 127.0 ± 16.0 125.6 ± 15.5 0.61 109.6 ± 10.6 112.1 ± 10.0 110.3 ± 9.7 0.033
DBP (mm Hg) 78.9 ± 11.4 77.1 ± 12.4 77.3 ± 10.2 0.88 68.6 ± 7.9 70.0 ± 7.4 69.2 ± 7.2 0.16
AST (IU/L) 34.0 ± 14.6 47.5 ± 26.4 57.5 ± 35.5 0.00017 19.3 ± 6.5 19.6 ± 6.5 21.2 ± 5.8 0.047
ALT (IU/L) 48.3 ± 24.6 76.9 ± 48.9 89.6 ± 57.0 4.7 × 10
-5 15.1 ± 5.5 15.5 ± 6.9 16.4 ± 6.2 0.36
Iron (ng/mL) 112.4 ± 28.7 106.1 ± 34.7 113.9 ± 33.1 0.66 ––– –
Ferritin (ng/mL) 168.8 ± 124.4 271.2 ± 268.6 276.3 ± 224.7 0.038 ––– –
Hyaluronic acid (ng/dL) 48.4 ± 47.4 39.7 ± 55.3 57.3 ± 74.0 0.022 ––– –
Type IV collagen 7S (ng/dL) 4.6 ± 1.9 4.6 ± 1.4 4.6 ± 1.2 0.76 ––– –
Steatosis grade 1.5 ± 0.6 1.6 ± 0.7 1.6 ± 0.6 0.57 ––– –
Fibrosis stage 0.7 ± 0.8 1.1 ± 0.9 1.2 ± 1.0 0.013 ––– –
Data are represented as the mean ± SD. AST, aspartate transaminase; ALT, alanine transaminase; BMI, body mass index; DBP, diastolic blood pressure; FBS, fasting
blood sugar; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; NAFLD, nonalcoholic fatty liver disease; SBP, systolic blood pressure. * The data of each
quantitative phenotype from NAFLD and control subjects were compared for the different rs738409 genotypes in patients with NAFLD and control subjects.
§P
values were analyzed using the Kruskal-Wallis test in each group of NAFLD and control subjects.
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between different genotypes in the NAFLD and control
subjects. Fasting plasma glucose and serum triglycerides
levels were low in patients with NAFLD harboring the
risk allele (G-allele) (Table 4 Additional file 2 Table S2).
In contrast, AST (P = 0.00017) and ALT (4.7 × 10
-5)
levels were significantly higher in these patients. Serum
AST and ALT levels were higher in the control subjects
harboring the risk allele, although differences were not
significant. Among the serum markers of liver fibrosis,
serum ferritin (P = 0.038) and hyaluronic acid (P =
0.022) were significantly higher in patients with NAFLD
harboring the G-allele.
To investigate the effects of age, gender, and BMI, we
attempted to perform linear multiple regression analysis
with plasma glucose, triglycerides, AST, ALT, ferritin,
and hyaluronic acid as the dependent variables. We
coded genotypes as 0, 1, or 2, depending on the number
of copies of the risk allele, and used age, gender, BMI,
or SNP as an explanatory variable. The values of trigly-
cerides, ferritin, and hyaluronic acid were logarithmically
transformed before performing multiple linear regres-
sion analysis, since these values had skewed distribution.
The G-allele of rs738409 was significantly associated
with increases in AST (P = 0.00013) and ALT (P =9 . 1
×1 0
-6) levels even after age, gender, and BMI were
included in the model in the NAFLD group (Table 5).
In the control group, the G-allele of rs738409 was not
significantly associated with differences in AST and
ALT levels. rs738409 was also associated with increased
serum ferritin levels (P = 0.014) but not with hyaluronic
acid levels. The G-allele was significantly associated with
decreased levels of triglycerides (P = 0.0034). The G-
allele was not associated with fasting plasma glucose
after being adjusted for age and gender and/or BMI.
The genotype of rs738409 may be related to the severity
of NAFLD.
Association between rs738409 genotypes and the
histological steatosis grade or fibrosis stage
We investigated the association between rs738409 geno-
types and the histological steatosis grade or fibrosis
stage. The results of the analysis revealed an additive
increase in the fibrosis stage in the patients with the G-
allele of rs738409 (P = 0.013 in the Kruskal-Wallis test)
(Table 4 and Additional file 2 Table S2). Multiple linear
regression analysis revealed that the rs738409 genotype
was significantly associated with the fibrosis stage, even
after age, gender, and BMI were included in this model
(P = 0.011; Table 5). Although rs738409 was identified
to be the variant associated with liver fat content, the
steatosis grade was not associated with the rs738409
genotype (Table 4 Additional file 2 Table S2).
Discussion
In 2 recent genome-wide association studies, PNPLA3
was found to be associated with liver-related conditions
[17,18]. Association of the G-allele of rs738409 with
increased liver fat content [20,22,23] and ALT levels
[21,24-26] has been replicated; hence, the influence of
this SNP to NAFLD was strongly suggested. The asso-
ciation of this SNP with the development of NAFLD
and liver damage in NAFLD has been shown in the
Argentinian and Caucasian populations [21,25]. There is
no report on the association between rs738409 and
NAFLD in the Japanese population. The results of the
present study indicated that the G-allele of rs738709 is
strongly associated with NAFLD (especially NASH);
increased plasma levels of ALT and AST; decreased
plasma levels of triglycerides; and the higher fibrosis
stage. Our results suggest that rs738409 may have an
important role in the progression of NAFLD in Japanese
individuals. NAFLD is closely related with metabolic
syndrome. In agreement, patients from the NAFLD
group had more metabolic disorders than patients from
the control group. Therefore, it is possible that the SNP
dosage does not directly affect the accumulation of liver
fat and/or progression of steatosis to NASH and fibrosis.
We should not exclude the possibility that metabolic
disorders, such as visceral adiposity and higher blood
lipids, directly affect the development and progression
of NAFLD.
Association of rs738409 with ALT and AST levels is
controversial. In Hispanics [17], Argentinians with
NAFLD [21], Italian adults with NAFLD [25], obese
Italian adults [24], and obese Italian children [26], the
G-allele of rs738409 was found to be significantly
related to increased ALT levels. In Finnish individuals
[20], obese Italian adults [24], obese Italian children
[26], and Argentinians with NAFLD [21], the G-allele of
rs738409 is significantly associated with increased AST
levels. However, in the African American, European
American [17], and German [23] populations, rs738409
is not associated with either ALT or AST levels. In our
study, associations between the G-allele of rs738409 and
increased levels of ALT and AST were observed only in
the NAFLD group. This may be because of population
bias, i.e., whether the subjects included adults or chil-
dren, general population, or patients with disease
(NAFLD or obesity). Variation of rs738409 was asso-
ciated with NAFLD. Therefore, the association of ALT
and/or AST levels with this variation may be affected by
the prevalence and severity of NAFLD in the subjects of
v a r i o u ss t u d i e s .I ti sa l s ol i k e l yt od i f f e ra m o n gv a r i o u s
ethnic groups because the G-allele frequency of
rs738409 in the Japanese control (44%) was similar to
that in the Hispanics (49%) but higher than that in the
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tinians (33%).
Kollerits et al. [33] reported that the G-allele of
rs738409 was associated with low total cholesterol and
low-density lipoprotein (LD L )c h o l e s t e r o lb u tn o tw i t h
HDL cholesterol or triglycerides. Speliotes et al.[ 3 4 ]
indicated that the G-allele is associated with decreased
triglycerides levels in NAFLD patients and that this
association is not observed in control subjects. In our
sample population, the G-allele of rs738409 was asso-
ciated with decreased levels of triglycerides in patients
with NAFLD but not in control subjects. This associa-
tion was significant after parameters of age, gender, BMI
and treatment of dyslipidemia were adjusted (P =
0.00040), excluding the possibility of the effect of the
treatment for dyslipidemia. SNP rs738409 was associated
with liver fibrosis in our and other studies [25,34,35].
The decreased levels of triglycerides in the NALFD
patients harboring the G-allele may be related to the
decreased production of triglycerides due to the severity
of the NASH fibrosis. The control group had no risk for
NAFLD and had normal liver function. Therefore,
Table 5 Multiple linear regression analysis for AST, ALT, triglycerides, ferritin, hyaluronic acid, steatosis grade, and
fibrosis stage
Explanatory variable Subjects Independent variable b SE P value
AST NAFLD Genotype (additive model, 0/1/2) 10.165 2.606 0.00013
Age (year) -0.162 0.153 0.29
Gender (Man/Women, 1/0) -4.967 4.335 0.25
BMI (kg/m
2) 0.711 0.380 0.063
Control Genotype (additive model, 0/1/2) 0.567 0.466 0.23
Age (year) 0.176 0.022 4.2 × 10
-14
Gender (Man/Women, 1/0) 0.226 0.775 0.77
BMI (kg/m
2) 0.120 0.167 0.47
ALT NAFLD Genotype (additive model, 0/1/2) 18.977 4.171 9.1 × 10
-6
Age (year) -1.125 0.244 7.1 × 10
-6
Gender (Man/Women, 1/0) 7.571 6.938 0.28
BMI (kg/m
2) 0.991 0.608 0.10
Control Genotype (additive model, 0/1/2) 0.417 0.477 0.38
Age (year) 0.120 0.023 2.5 × 10
-7
Gender (Man/Women, 1/0) 2.131 0.793 0.0076
BMI (kg/m
2) 0.370 0.171 0.031
Triglycerides NAFLD Genotype (additive model, 0/1/2) -0.050 0.017 0.0035
Age (year) -0.003 0.001 0.0051
Gender (Man/Women, 1/0) 0.102 0.023 0.00038
BMI (kg/m
2) -0.001 0.002 0.66
Ferritin NAFLD Genotype (additive model, 0/1/2) 0.107 0.043 0.014
Age (year) 0.005 0.002 0.056
Gender (Man/Women, 1/0) 0.298 0.069 2.9 × 10
-5
BMI (kg/m
2) 0.009 0.006 0.11
Hyaluronic acid NAFLD Genotype (additive model, 0/1/2) 0.023 0.036 0.52
Age (year) 0.016 0.002 1.6 × 10
-12
Gender (Man/Women, 1/0) -0.010 0.059 0.87
BMI (kg/m
2) 0.014 0.005 0.0047
Steatosis grade NAFLD Genotype (additive model, 0/1/2) 0.041 0.059 0.48
Age (year) -0.010 0.003 0.0037
Gender (Man/Women, 1/0) -0.106 0.098 0.28
BMI (kg/m
2) 0.022 0.009 0.010
Fibrosis stage NAFLD Genotype (additive model, 0/1/2) 0.211 0.082 0.011
Age (year) 0.013 0.005 0.0058
Gender (Man/Women, 1/0) 0.184 0.136 0.18
BMI (kg/m
2) 0.046 0.012 0.00016
AST, aspartate transaminase; ALT, alanine transaminase; BMI, body mass index; NAFLD, nonalcoholic fatty liver disease. The values of triglycerides, ferritin, and
hyaluronic acid were logarithmically transformed.
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jects without NAFLD.
It has been hypothesized that NASH is induced in 2
consecutive steps (the so-called 2-hit hypothesis): (i)
excess fat accumulation in the liver and (ii) subsequent
necroinflammation in the liver [36]. The histological
steatosis grade was higher in patients with NASH than
in those with simple steatosis. Moreover, the association
study showed that the risk allele (G) frequency of
rs738409 was significantly higher in the NASH group
than in the simple steatosis group. However, the steato-
sis grade was not found to be associated with the
rs738409 genotype, although rs738409 has been pre-
viously associated with liver fat content [17,20,22,23].
The statistical power for association of rs738409 with
the histological steatosis grade may be lower than the
association with liver fat content, since the histological
steatosis grade determined by the percentage of hepato-
cytes containing fat droplets does not represent the
actual fat content. Indeed, the association between
rs738409 and histological steatosis grade is controversial
[25,34,35]. rs738409 is a missense variation (I148M) in
PNPLA3. Triglyceride lipase activity of mutant PNPLA3
(I148M) was completely abolished; this led to increased
triglyceride accumulation in the human hepatoma cells,
which exhibited more and larger lipid droplets [37].
Furthermore, acute overexpression of the mutant pro-
tein in mice led to a 2-fold increase in hepatic fat.
These experiments and several reports indicating the
association between rs738409 and liver fat accumulation
suggest that the I148 M variant may affect lipid accu-
mulation in the fatty liver. Further investigations would
be necessary to elucidate whether rs738409 is associated
with liver fat accumulation in the Japanese population.
Serum ferritin, hyaluronic acid, and type IV collagen
7S levels were higher in theN A S Hp a t i e n tg r o u pt h a n
in the simple steatosis group as previously reported
(Table 2) [38-40]. High rates of hyperferritinemia and
increased hepatic iron stores have been demonstrated in
NASH patients [40]. Iron is considered a putative ele-
ment that interacts with oxygen radicals in liver damage
and fibrosis. There is strong evidence from in vitro and
in vivo studies that iron overload enhances oxidative
stress [41]. Iron can also promote fibrosis through hepa-
tocellular necrosis and inflammation with activation of
Kupffer cells (liver macrophages), which release profi-
brogenic mediators [42]. We showed that serum ferritin
was increased in NAFLD patients harboring the G-allele.
High serum ferritin levels found in hepatic iron accumu-
lation and overload conditions enhance oxidative stress
and insulin resistance. Our results and the data previous
reported [25,34,35] indicate that rs738409 is likely to be
related to liver fibrosis in NAFLD. Although more
studies are required to elucidate the precise mechan-
isms, we suggest that PNPLA3 induces fatty liver and
leads to necroinflammation through oxidative stress
induced by high levels of iron in the liver.
Serum hyaluronic acid levels are elevated during accel-
erated deposition of extracellular matrix due to the
upregulation of hyaluronic acid production by matrix-
producing cells such as hepatic stellate cells and fibro-
blasts, and to the downregulation of its clearance by
sinusoidal endothelial cells [43,44]. Serum hyaluronic acid
appears to be a relatively accurate predictor of advanced
fibrosis in NAFLD [39]. Type IV collagen is one of the
extracellular matrix components produced by hepatic
fibroblasts, hepatic stellate cells, and myofibroblasts.
Serum type IV collagen 7S domain levels increase
as fibrosis worsens as a result of synthesis by matrix-
producing cells induced by liver fibrosis [45]. To ascertain
whether the serum levels of hyaluronic acid and type IV
collagen 7S domain are associated with rs738409, it would
be necessary to examine a bigger sample of NAFLD
patients, since serum levels can be affected by various
conditions such as medical treatment and life-style.
Conclusions
In conclusion, we have shown that the G-allele of
rs738409 renders the Japanese population susceptible to
NAFLD. We have also shown that rs738409 is asso-
ciated with plasma ALT, AST, and triglycerides levels,
and the fibrosis stage. Our study suggests that PNPLA3
may be involved in the progression of NAFLD in the
Japanese population.
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